Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis

Phase 3 Active not recruiting 12 enrolled Alexion Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to characterize the pharmacokinetics and pharmacodynamics of treatment with ravulizumab intravenous infusion in pediatric participants with gMG.

Timeline

Start: 2023-06-24
Primary completion: 2026-07-15
Completion: 2028-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ravulizumab	Monoclonal antibody	—	Intravenous

Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis

Summary

Timeline

Drugs

Indications